![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GP Thomas, GR Ferrier and SE Howlett
Department of Pharmacology, Delhousie University, Halifax, Nova Scotia, Canada.
The purpose of this study was to determine whether specific angiotensin II (AII) type 1 receptor blockade with losartan would affect arrhythmia generation in an isolated guinea pig ventricular model of simulated ischemia and reperfusion. Effects of losartan were evaluated in the presence and absence of exogenous AII. Transmembrane potentials and an electrocardiogram were recorded during perfusion with normal Tyrode's solution, exposure to simulated ischemia for 15 min (hypoxia, acidosis, lactate, hyperkalemia, glucose-free) and reperfusion for 30 min. Under normal conditions, losartan did not affect endocardial or transmural conduction times, action potential duration at 90% repolarization or effective refractory period (ERP). However, losartan and AII each had significant effects on electrophysiological parameters during simulated ischemia and reperfusion. Further, losartan and AII, both independently and in combination, exerted antiarrhythmic effects in early reperfusion. Neither losartan nor AII affected action potential duration at 90% repolarization during simulated ischemia or reperfusion. However, AII exerted antiarrhythmic effects by preventing pronounced shortening of ERP in simulated ischemia and early reperfusion. Losartan by itself had no effect on ERP, but completely blocked the antiarrhythmic action of AII on ERP. Nevertheless, losartan preserved antiarrhythmic efficacy by attenuating prolongation of transmural conduction times in stimulated ischemia and early reperfusion. This antiarrhythmic action occurred in the absence or presence of AII. Our results indicate that losartan has antiarrhythmic efficacy which is independent of AII type 1 receptor blockade.
This article has been cited by other articles:
|
|
 |
|
  M. Krop, J. H.M. van Esch, and A.H. J. Danser Letter by Krop et al Regarding Article, "Role of p90 Ribosomal S6 Kinase-Mediated Prorenin-Converting Enzyme in Ischemic and Diabetic Myocardium" Circulation, October 24, 2006; 114(17): e556 - e556. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zakynthinos, Ch. Pierrutsakos, Z. Daniil, and D. Papadogiannis Losartan Controlled Blood Pressure and Reduced Left Ventricular Hypertrophy But Did Not Alter Arrhythmias in Hypertensive Men with Preserved Systolic Function Angiology, July 1, 2005; 56(4): 439 - 449. [Abstract] [PDF]
|
|
|
|
 |
|
 G. R. Ferrier and S. E. Howlett Pretreatment with Pinacidil Promotes Arrhythmias in an Isolated Tissue Model of Cardiac Ischemia and Reperfusion J. Pharmacol. Exp. Ther., May 1, 2005; 313(2): 823 - 830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Louch, G. R. Ferrier, and S. E. Howlett Attentuation of Cardiac Stunning by Losartan in a Cellular Model of Ischemia and Reperfusion Is Accompanied by Increased Sarcoplasmic Reticulum Ca2+ Stores and Prevention of Cytosolic Ca2+ Elevation J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 238 - 247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Galinanes and A. G Fowler Role of clinical pathologies in myocardial injury following ischaemia and reperfusion Cardiovasc Res, February 15, 2004; 61(3): 512 - 521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Louch, G. R. Ferrier, and S. E. Howlett Losartan Improves Recovery of Contraction and Inhibits Transient Inward Current in a Cellular Model of Cardiac Ischemia and Reperfusion J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 697 - 704. [Abstract] [Full Text]
|
|
|
|
|
|
R. Caballero, E. Delpon, C. Valenzuela, M. Longobardo, and J. Tamargo Losartan and Its Metabolite E3174 Modify Cardiac Delayed Rectifier K+ Currents Circulation, March 14, 2000; 101(10): 1199 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. R. Ford, A. S. Clanachan, and B. I. Jugdutt Characterization of Cardioprotection Mediated by AT2 Receptor Antagonism After Ischemia-Reperfusion in Isolated Working Rat Hearts Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(3): 211 - 221. [Abstract] [PDF]
|
|
|
|
|
|
B. I. Jugdutt, Yi Xu, M. Balghith, R. Moudgil, and V. Menon Cardioprotection Induced by AT1R Blockade After Reperfused Myocardial Infarction: Association With Regional Increase in AT2R, IP3R and PKC{varepsilon} Proteins and cGMP Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 2000; 5(4): 301 - 311. [Abstract] [PDF]
|
|
|
|
 |
|
 J. J. Lynch Jr., G. L. Stump, A. A. Wallace, C. A. Painter, J. M. Thomas, S. E. Kusma, R. J. Gould, and W. Grossman EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction J. Am. Coll. Cardiol., September 1, 1999; 34(3): 876 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jalowy, R. Schulz, H. Dorge, M. Behrends, and G. Heusch Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs J. Am. Coll. Cardiol., November 15, 1998; 32(6): 1787 - 1796. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
